SEC22B

Across TCGA pan-cancer cohorts, SEC22B mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of SEC22B’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where SEC22B mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SEC22B is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

LUAD, CCRCC, and LSCC are the cancer types where SEC22B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SEC22B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	II,III,IV	+0.334	<.001	8	view →
CCRCC	All	II,III,IV	+0.208	<.001	8	view →
LSCC	All	All	+0.180	<.001	7	view →
COAD	All	All	+0.085	.001	7	view →
OV	All	All	+0.410	.002	2	view →
PDAC	All	All	−0.243	.009	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

SEC22B–LUAD

Open the LUAD breakdown →